Caricamento pagina

How RTU Solutions Can Meet GMP Annex 1 Requirements

<span id="hs_cos_wrapper_name" class="hs_cos_wrapper hs_cos_wrapper_meta_field hs_cos_wrapper_type_text" style="" data-hs-cos-general-type="meta_field" data-hs-cos-type="text" >How RTU Solutions Can Meet GMP Annex 1 Requirements</span>

Abstract

The updated EU GMP Annex 1 guidelines have introduced heightened expectations around contamination control, quality risk management, and the implementation of comprehensive Contamination Control Strategies (CCS) for sterile manufacturing operations. These requirements are driving pharmaceutical companies to reassess their fill & finish processes, seeking solutions that can help reduce operational complexity while maintaining the highest quality standards.

In this webinar, experts from Stevanato Group explore how Ready-to-Use (RTU) vial and cartridge platforms can support Annex 1 compliance by eliminating critical preparation steps such as washing, depyrogenation, and sterilization. It will be illustrated how sterilized containment solutions can help reduce contamination risks, simplify manufacturing operations, improve process efficiency, and accelerate time-to-market while supporting robust contamination control strategies.

Key Learning Objectives:

  • Understand the key GMP Annex 1 updates and their impact on sterile manufacturing operations, contamination control strategies (CCS), and quality risk management approaches.
  • Learn how Ready-to-Use vial and cartridge platforms can help reduce operational complexity by eliminating washing, depyrogenation, and sterilization activities while minimizing contamination risks.
  • Discover the operational, quality, and time-to-market advantages that RTU solutions can provide compared with conventional container preparation processes.
Stevanato Group
Stevanato Group

Stevanato Group is a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle at each of the development, clinical, and commercial stages.

Other webinars

通过数字生态系统释放自动目视检测的性能潜力

1 minute read

ADC 药品:风险管理与稳定性提升解决方案

1 minute read

连接可用性与可持续性:穿戴式给药系统

1 minute read